Sponsored

First FDA-Approved Oral Liquid Sitagliptin for Adults With Type 2 Diabetes

October 27th 2025

Early Real-World Experience with VIMKUNYA Consistent with Clinical Trial Findings

October 23rd 2025

An Over-the-Counter Evidence-Based Approach to Reducing the Risk of Antibiotic-Associated Diarrhea

May 22nd 2025

For Optimal Bioavailability, Administer Dronedarone With a Complete Meal

BySachin Shah, PharmD, FACC, FAHA,Kristen Bova Campbell, PharmD, CPP, BCPS

April 10th 2025

Bioavailability of dronedarone is markedly increased when administered with food. To maximize absorption, patients should take dronedarone with a complete meal (ideally >500 calories).

Tim Cernohous, SVP & President, Community Retail & Long-Term Care, Cencora, reflects on ThoughtSpot 2024

September 17th 2024

Adult Hepatitis B Vaccine Recommendations: Identify, Strongly Recommend, Protect

February 23rd 2024

Pharmacist Appreciation

December 19th 2022

Tim Whitten, BSPharm, MBA, CEO & President of Taiho Oncology Inc discusses the critical impacts of pharmacists across the health care landscape.

Announcing Exciting News From A Pharmacist Advocate!

September 14th 2022

First FDA-Approved Oral Liquid Sitagliptin for Adults With Type 2 Diabetes

Early Real-World Experience with VIMKUNYA Consistent with Clinical Trial Findings

An Over-the-Counter Evidence-Based Approach to Reducing the Risk of Antibiotic-Associated Diarrhea

For Optimal Bioavailability, Administer Dronedarone With a Complete Meal

Tim Cernohous, SVP & President, Community Retail & Long-Term Care, Cencora, reflects on ThoughtSpot 2024

Adult Hepatitis B Vaccine Recommendations: Identify, Strongly Recommend, Protect

Pharmacist Appreciation

Announcing Exciting News From A Pharmacist Advocate!

Trending on Pharmacy Times

Cyclosporiasis on the Rise in the United States, Exceeding 450 Cases

Kidney Disease Rates Hold Steady for a Decade as Diabetes-Driven Cases Climb

Same-Day COVID-19 and Flu Vaccination Does Not Raise Adverse Event Risk, Large VA Study Finds

Reducing Recurrence in C Difficile Infection

Challenging “Obesity Paradox,” Obesity-Driven Immune Suppression May Increase NSCLC Risk

Sponsored

First FDA-Approved Oral Liquid Sitagliptin for Adults With Type 2 Diabetes

Early Real-World Experience with VIMKUNYA Consistent with Clinical Trial Findings

An Over-the-Counter Evidence-Based Approach to Reducing the Risk of Antibiotic-Associated Diarrhea

For Optimal Bioavailability, Administer Dronedarone With a Complete Meal

Tim Cernohous, SVP & President, Community Retail & Long-Term Care, Cencora, reflects on ThoughtSpot 2024

Adult Hepatitis B Vaccine Recommendations: Identify, Strongly Recommend, Protect

Pharmacist Appreciation

Announcing Exciting News From A Pharmacist Advocate!

Trending on Pharmacy Times

Cyclosporiasis on the Rise in the United States, Exceeding 450 Cases

Kidney Disease Rates Hold Steady for a Decade as Diabetes-Driven Cases Climb

Same-Day COVID-19 and Flu Vaccination Does Not Raise Adverse Event Risk, Large VA Study Finds

Reducing Recurrence in C Difficile Infection

Challenging “Obesity Paradox,” Obesity-Driven Immune Suppression May Increase NSCLC Risk

Reducing Recurrence in C Difficile Infection